Innovation Pharmaceuticals Inc (IPIX)

[RJFL]

"eventhelosers"

This is the cut/paste from the referenced study (it is 55 months duration) if it is the correct one.


Overview


Research Study Summary

A clinical research study of RO5429083 and cytarabine for the treatment of Myelogenous Leukemia, Acute


Research Study Title

Open Label, Multicenter, Dose Escalation Phase 1a/b Study of RO5429083, Administered as Intravenous Infusion Alone or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia (AML).

Purpose

This multi-center, open-label study will evaluate the safety, pharmacokinetics, pharmacodynamics and efficacy of RO5429083 alone and in combination with cytarabine in patients with acute myelogenous leukemia. In Part A, patients will receive multiple escalating doses of RO5429083 intravenously. In Part B, patients will receive RO5429083 plus up to 4 cycles of cytarabine (1000 mg/m2 iv daily for 5 consecutive days). Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs.



Phase

1


Gender

Both Male and Female


Age

18 and up


Overall Status

Recruiting


Lead Sponsor

Hoffmann-La Roche


Duration

55 Months


Facility Type

N/A